To identify sequence domains important for the neurotoxic and neuroprotective activities of the prion protein (PrP), we have engineered transgenic mice that express a form of murine PrP deleted for a conserved block of 21 amino acids (residues 105-125) in the unstructured, N-terminal tail of the protein. These mice spontaneously developed a severe neurodegenerative illness that was lethal within 1 week of birth in the absence of endogenous PrP. This phenotype was reversed in a dose-dependent fashion by coexpression of wild-type PrP, with five-fold overexpression delaying death beyond 1 year. The phenotype of Tg(PrPD105-125) mice is reminiscent of, but much more severe than, those described in mice that express PrP harboring larger deletions of the N-terminus, and in mice that ectopically express Doppel, a PrP paralog, in the CNS. The dramatically increased toxicity of PrPD105-125 is most consistent with a model in which this protein has greatly enhanced affinity for a hypothetical receptor that serves to transduce the toxic signal. We speculate that altered binding interactions involving the 105-125 region of PrP may also play a role in generating neurotoxic signals during prion infection.
Introduction
Prion diseases, also known as transmissible spongiform encephalopathies, are fatal neurodegenerative disorders that affect humans and animals. The infectious agent (prion) that causes these diseases is composed primarily of the protein PrP Sc (Prusiner, 1998; Aguzzi and Polymenidou, 2004 . Attempts to deduce the function of PrP C from the phenotypes of prion protein (PrP)-null mice have been unrewarding, as lines of these mice in which the adjacent Doppel (Dpl) gene is not artifactually upregulated display no major anatomical or developmental deficits (Bü eler et al, 1992; Manson et al, 1994) .
Recent evidence raises the intriguing possibility that the normal physiological activity of PrP C is in some way required for manifestation of prion-induced neuropathology. For example, PrP C expression is essential to render neurons in the brain susceptible to the toxic effects of PrP Sc emanating from grafted brain tissue or from nearby astrocytes (Mallucci et al, 2003) . In addition, scrapie neuropathology is minimal in transgenic mice that express PrP C lacking a C-terminal, glycolipid anchor, implying that membrane attachment of PrP C is essential for transducing a PrP Sc -derived neurotoxic signal (Chesebro et al, 2005) . The mechanism by which PrP C contributes to prion-induced neurotoxicity is unclear. One hypothesis is that PrP C normally serves a neuroprotective function that is abolished or subverted by interaction with PrP Sc (Harris and True, 2006) . In fact, several recent experiments have uncovered a cytoprotective activity of PrP C . PrP overexpression rescues cultured neurons, some mammalian cell lines, and yeast from several kinds of death-inducing stimuli (Kuwahara et al, 1999; Bounhar et al, 2001; DiarraMehrpour et al, 2004; Li and Harris, 2005; . Moreover, endogenous PrP has been found to protect cultured neurons against oxidative stress, and brain tissue against ischemia, hypoxia, or trauma in vivo (Brown et al, 2002; Hoshino et al, 2003; McLennan et al, 2004; Spudich et al, 2005) . Nevertheless, how the putative neuroprotective activity of PrP C might be altered during prion diseases to produce a neurotoxic effect remains unknown.
A compelling demonstration of two contrasting biological activities of PrP C , one neurotoxic and the other neuroprotective, comes from analysis of transgenic mice expressing certain N-terminally truncated forms of PrP (PrPD32-134 and PrPD32-121, collectively referred to as PrPDN). These mice suffer from a fatal neurodegenerative illness characterized by massive apoptosis of cerebellar granule neurons or Purkinje cells (depending on where the transgene is expressed) (Shmerling et al, 1998; Flechsig et al, 2003) . Importantly, this phenotype is observed only in Prn-p 0/0 mice that do not express endogenous PrP. Coexpression of wild-type PrP, either from the endogenous Prn-p allele or from a second transgene, completely prevents neurodegeneration in Tg(PrPDN) mice. A similar phenomenon has been observed in mice that ectopically express Dpl, a PrP paralog that is structurally similar to PrPDN. The Dpl gene, which is normally expressed primarily in testis, is expressed ectopically in the brain of certain lines of Prn-p 0/0 mice as a result of intergenic splicing events between the adjacent PrP and Dpl genes (Sakaguchi et al, 1996; Moore et al, 1999; Li et al, 2000; Rossi et al, 2001 ). These lines, as well as transgenic lines expressing elevated levels of Dpl in the brain, display a neurodegenerative phenotype that is stoichiometrically rescued by wild-type PrP (Nishida et al, 1999; Moore et al, 2001; Rossi et al, 2001; Anderson et al, 2004) . Taken together with the previously cited evidence for PrP cytoprotection in vitro, the experiments on transgenic mice expressing PrPDN and Dpl suggest that PrP C possesses neuroprotective properties, but that deletion of specific regions of the molecule can unmask powerful neurotoxic activities.
Several considerations indicate that the central region of the PrP sequence, comprising residues 105-125 in the mouse protein (residues 106-126 in the human protein), constitutes a critical determinant of the neurotoxic and neuroprotective activities of PrP. First, it was reported in the original work by Shmerling et al (1998) , that transgenic mice that express PrP molecules carrying N-terminal deletions up through residue 106 were normal, whereas mice expressing PrP molecules with deletions that extended to residue 121 or 134 displayed a neurodegenerative phenotype. Second, a region homologous to PrP residues 105-125 is missing in Dpl, which consists of a three-helix structure similar to that found in the C-terminal half of PrP (Mo et al, 2001; Luhrs et al, 2003) . Third, it has been found that the synthetic peptide PrP106-126 is toxic when applied to cultured neurons from Prn-p +/+ but not from Prn-p 0/0 mice Brown et al, 1994) . Although the mechanism of this toxicity is unknown, its dependence on expression of wild-type PrP suggests some connection with the normal biological activity of PrP C . To test the role of residues 105-125 in the biological activity of PrP, we created transgenic mice expressing PrP molecules harboring a deletion of this 21 amino-acid region. We found that these mice displayed a dramatic neurodegenerative phenotype that resulted in lethality as early as 1 week after birth. This phenotype was reversed in a dose-dependent fashion by coexpression of wild-type PrP. Our results define a critical functional domain of PrP that determines its neurotoxic and neuroprotective activities. In addition, our data suggest a model for the normal, biological function of PrP C , and how this function may be altered in prion diseases.
Results

Generation of transgenic mice and analysis of protein expression
For convenience, we will refer to PrP carrying a deletion of residues 105-125 as PrPDCR, as the deleted region lies in the central region of the protein. The deleted segment encompasses a positively charged region along with part of the adjacent hydrophobic domain ( Figure 1A) . A cDNA encoding murine PrPDCR was introduced into the moPrP.Xho vector (Borchelt et al, 1996) . This vector drives transgene expression under control of a Prn-p promoter in a pattern similar to that of endogenous PrP, with the exception that there is no expression in cerebellar Purkinje cells . Founder mice (designated A, B, and E) were obtained by pronuclear injection of fertilized oocytes from C57BL/ 6J Â CBA/J parents. Initially, the founders were bred to Prn-p 0/0 mice to produce offspring carrying a single copy of both the PrPDCR transgene and the endogenous Prn-p gene.
Brain homogenates from Tg(PrPDCR +/0 )/Prn-p +/0 mice were subjected to Western blotting using anti-PrP monoclonal antibody 8H4 following enzymatic deglycosylation with PNGase. PrPDCR could then be distinguished from fulllength, endogenous PrP owing to the small size difference (B2 kDa) between the two polypeptide chains in the absence of N-linked oligosaccharides ( Figure 1B) . By quantitating the relative amounts of the two bands, we determined that the expression level of PrPDCR in the A and E lines was similar to that of endogenous PrP in these Prn-p +/0 mice (i.e., 0.5 Â with respect to Prn-p +/+ mice), whereas the expression level of PrPDCR in the B line was B2-fold higher (1 Â ).
Neurological symptoms of Tg(DCR) mice and amelioration by wild-type PrP F1 offspring from all three founders that were hemizygous for the PrPDCR transgene and heterozygous for the endogenous Prn-p gene became ill within 2 weeks of birth and died within 1 month (Table I ; lines 1, 3, and 6). Symptoms in these neonatal animals included decreased body size and weight, immobility, difficulty righting, myoclonic spasms, and tremor.
By analogy to the case of Tg(PrPDN) mice expressing N-terminally truncated PrP, we hypothesized that coexpression of wild-type PrP would ameliorate the symptoms in Tg(DCR) mice. To maintain the lines, we therefore bred the A, B, and E founders to Tga20 mice , which overexpress wild-type PrP by five-fold when the transgene array is present in the hemizygous state. Tg(DCR-A +/0 ) and Tg(DCR-E +/0 ) mice on the Tga20 +/0 /PrP +/0 background did not develop symptoms until B280 days and survived more than 360 days (Table I; background, and this mouse became ill at 43 days of age and did not produce offspring (Table I ; line 4). The earlier age of disease onset in Tg(DCR-B) mice correlates with the higher expression level of mutant PrP in this line ( Figure 1B) .
In a previous study, we found that Tg(WT-E1) mice, which express wild-type PrP from the moPrP.Xho vector at a level four-fold higher than endogenous PrP, never develop clinical symptoms (Chiesa et al, 1998) . Tga20 mice also do not show spontaneous illness . Thus, the neurological illness seen in Tg(DCR) mice is specifically related in a dose-dependent fashion to the presence of the PrPDCR protein.
To investigate quantitatively the relationship between clinical illness and wild-type PrP expression levels, we bred Tg(DCR)/Tga20 +/0 /PrP +/0 mice from the E line to either Prn-p 0/0 or Prn-p +/+ mice, to obtain Tg(DCR-E +/0 ) offspring expressing different amounts of wild-type PrP encoded by either the endogenous Prn-p gene or the Tga20 transgene. We found that development of symptoms in Tg(DCR) mice was inversely correlated with the expression level of wild-type PrP. Tg(DCR-E +/0 )/Tga20 0/0 /Prn-p 0/0 mice, which completely lack wild-type PrP, appeared runted and displayed righting difficulty and myoclonic spasms by 4 days after birth ( Figure 2) ; these animals died within 1 week (Table I ; line 5). Coexpression of wild-type PrP ameliorated the phenotype in a dose-dependent fashion: one Prn-p allele (0.5 Â expression level) delayed death until 25 days (Table I ; line 6) and two Prn-p alleles (1 Â expression level) delayed death until 48 days (Table I ; line 7). The presence of one Tga20 allele either with or without a Prn-p allele, (5-6 Â expression level), delayed symptom onset to 250-300 days and allowed the mice to survive 41 year (Table I ; lines 8-10) (Figure 2 ). Symptoms in older, clinically ill Tg(DCR-E +/0 )/Tga20 +/0 mice included coarse tremor, staggering gait, hind limb paresis, and difficulty righting.
Neuropathology in Tg(DCR) mice
Compared to non-transgenic littermates ( Figure 3C ), symptomatic mice expressing PrPDCR showed marked cerebellar atrophy, with reduction in the thickness of the granule cell and molecular layers ( Figure 3A ). There was a dramatic decrease in the number and density of cerebellar granule cells ( Figure 3 , compare D to F). In contrast, Purkinje cell number was unaffected ( Figure 3 , compare G to I). Immunohistochemical staining for glial fibrillary acidic protein (GFAP) demonstrated gliosis and astrocytic hypertrophy, which were most prominent in the granule cell and molecular layers of the cerebellar cortex ( Figure 3 , compare J to L). Consistent with the clinical observations, overexpression of wild-type PrP from the Tga20 transgene completely rescued cerebellar atrophy, granule cell loss, and astrogliosis in Tg(DCR) mice at 25 days of age ( Figure 3B , E, and K). Based on hematoxylin and eosin staining, there were no obvious neuropathological abnormalities in areas of the brain outside of the cerebellum (not shown). In a previous study, we did not observe any histological abnormalities in ) mice at 3 days of age. All mice were on the Prn-p 0/0 background. The Tg(DCR) mouse, which completely lacks wild-type PrP, is runted and immobile. In contrast, two Tg(DCR)/Tga20 +/0 mice, which express 5 Â the endogenous level of wild-type PrP, are healthy, similar to a nontransgenic Prn-p 0/0 mouse (non-Tg).
Tg(WT-E1) mice overexpressing wild-type PrP by four-fold (Chiesa et al, 1998) . To further explore the mechanism underlying neuronal degeneration in Tg(DCR) mice, brain sections of symptomatic Tg(DCR) mice were analyzed by TUNEL as well as by immunocytochemical staining with antibodies to activated caspase-3. Degenerating cerebellar granule cells were strongly TUNEL-positive ( Figure 4A ), and some cells also stained positively for activated caspase-3 ( Figure 4D ). Occasional TUNEL-positive cells were also observed in the hippocampus and neocortex, although loss of neurons in these regions was not obvious in hematoxylin-and eosinstained sections (not shown). Introduction of the Tga20 transgene abrogated appearance of TUNEL-and caspase-3-positive neurons in the cerebellum ( Figure 4B and E). Only very rare cells positive for these markers were observed in age-matched, non-transgenic littermates ( Figure 4C and F) . Taken together, these results indicate that expression of PrPDCR causes granule neurons to degenerate via an apoptotic process that is abrogated by overexpression of wild-type PrP. Radovanovic et al (2005) reported that mice expressing PrPDN and Dpl display a leukoencephalopathy characterized by vacuolar degeneration of white matter regions of the brain and spinal cord, accompanied by axonal loss and deterioration of myelin sheaths. We observed similar abnormalities in older, symptomatic Tg(DCR)/Tga20 +/0 mice. Coarse vacuolation was seen in the cerebellar white matter ( Figure 5A ), as well as in white matter tracts of the spinal cord ( Figure 5C ). In semi-thin plastic sections of the spinal cord white matter from Tg(DCR)/Tga20 +/0 mice, we observed extensive loss of myelinated axons, accompanied by the presence of large vacuoles and degeneration of myelin sheaths into condensed spheroid bodies ( Figure 5E ). Interestingly, these mice did not display significant cerebellar granule cell loss ( Figure 5A ). This result suggests that leukoencephalopathy and granule cell degeneration are independent processes that both contribute to clinical symptoms in Tg(DCR) mice, and that overexpression of wild-type PrP rescues granule cell apoptosis more effectively than white matter degeneration. No white matter pathology was observed in Tga20 mice in the absence of the PrPDCR transgene ( Figure 5B , D, and F).
Biochemical and cell biological properties of PrPDCR
We performed several experiments to determine whether abnormalities in the biochemical properties or cellular localization of PrPDCR could contribute to the phenotype of Tg(DCR) mice. For these experiments, we utilized Tg(DCR) mice that lacked wild-type PrP to allow selective antibody recognition of the mutant protein. Similar to wild-type PrP, PrPDCR displayed three major bands on Western blots, representing di-, mono-, and unglycosylated isoforms, with the diglycosylated form predominating ( Figure 6A , lanes 1 and 3). Following treatment with PNGase F, wild-type PrP appeared as two bands of 30 and 19 kDa, representing unglycosylated versions of full-length PrP and the C1 fragment, respectively ( Figure 6A, lane 4) . The latter fragment is produced physiologically by cleavage at approximately residue 110 (Harris et al, 1993; Chen et al, 1995) . In contrast, PNGase treatment of PrPDCR produced primarily a single band of 27 kDa, representing an unglycosylated version of the uncleaved protein ( Figure 6A , lane 2). PrPDCR did not produce a fragment equivalent to C1, consistent with the absence of the cleavage site in the deleted protein. These results indicate that PrPDCR is glycosylated like wild-type PrP, and is therefore processed through the secretory pathway, although it is not subject to cleavage at the C1 site.
We tested whether PrPDCR in the brains of transgenic mice adopted any of the biochemical properties characteristic of PrP Sc , including detergent insolubility (assayed by ultracentrifugation) and protease resistance (assayed by treatment with proteinase K). We found that, like wild-type PrP, PrPDCR remained in the supernatant fraction after ultracentrifugation ( Figure 6B) , and was completely digested by concentrations of proteinase K as low as 2.5 mg/ml ( Figure 6C ). Under the 
same conditions, PrP
Sc from scrapie-infected brain as well as mutant PrP from the brains of Tg(PG14) mice is pelleted by ultracentrifugation and produces a protease-resistant fragment (PrP27-30) after digestion with proteinase K (Chiesa et al, 1998; data not shown) .
To analyze the localization of PrPDCR, cerebellar granule neurons cultured from postnatal day 3 mouse pups were surface-stained with anti-PrP monoclonal antibody 8H4. PrPDCR was found to be uniformly distributed on the surface of cell bodies and neurites, similar to wild-type PrP on neurons from Prn-p +/0 mice ( Figure 7A and B) . The distribution of PrPDCR was also similar to that of wild-type PrP in immunostained cryostat sections of the cerebellum from postnatal day 6 mice ( Figure 7D and E). In both Tg(DCR) and Prn-p +/0 mice, PrP was present throughout the internal and external granule cell layers. There was no evidence for the presence of aggregates of PrPDCR. The specificity of antibody staining was confirmed by the lack of signal on cultured granule neurons and brain sections from Prn-p 0/0 mice ( Figure 7C and F) . The distribution of PrP in other brain regions, including the hippocampus and neocortex, was also similar in Tg(DCR) and Prn-p +/0 mice (data not shown). Taken together, these results indicate that deletion of residues 105-125 did not induce PrP to acquire biochemical properties of PrP Sc and did not substantially alter its cellular or anatomical distribution.
Discussion
We have engineered transgenic mice that express a form of PrP deleted for a conserved block of 21 amino acids in the central region of the protein (residues 105-125). These mice spontaneously develop a highly lethal neurodegenerative illness that is reversed in a dose-dependent manner by coexpression of wild-type PrP. This phenotype is reminiscent of, but much more severe than, those described in mice that express PrP harboring larger deletions of the N-terminus (D32-121 and D32-134), and in mice that ectopically express Dpl in the CNS. Our results define the 105-125 region as a crucial determinant of the neurotoxic and neuroprotective activities of PrP. These data also suggest new models for the normal, biological function of PrP C and how this function may be subverted to generate neurotoxic signals during prion infection.
A common mechanism of neurotoxicity
It was previously reported that mice expressing N-terminally deleted forms of PrP (D32-121 and D32-134, collectively referred to as PrPDN) developed a neurodegenerative phenotype that was rescued by coexpression of endogenous, wildtype PrP (Shmerling et al, 1998; Flechsig et al, 2003) . A neurodegenerative illness was also produced by ectopic expression in the CNS of Dpl, a PrP paralog that resembles PrPDN, as it consists of a three-helix structure homologous to the C-terminal half of PrP without the flexible, N-terminal tail (Sakaguchi et al, 1996; Moore et al, 1999 Moore et al, , 2001 Nishida et al, 1999; Rossi et al, 2001; Anderson et al, 2004) . The Dpl phenotype was also abrogated by coexpression of wild-type PrP.
It seems very likely that the same molecular mechanism underlies the neurotoxicity of PrPDCR, PrPDN, and Dpl. All three proteins lack a portion of the flexible, N-terminal tail found in full-length PrP, and the toxicity of each is antagonized by coexpression of wild-type PrP. In addition, it was previously reported that mice expressing PrP molecules deleted from residue 32 through residue 80, 93, or 106 are normal, whereas mice expressing PrP molecules with deletions that extend to residue 121 or 134 display a neurodegenerative phenotype (Shmerling et al, 1998) . Thus, it is likely that PrP residues 105-125 constitute a critical functional domain whose absence is responsible for the neurotoxicity of both PrPDCR and PrPDN, and that the absence of a homologous domain in Dpl underlies the pathogenicity of this protein as well.
PrPDCR, PrPDN, and Dpl also produce similar neuropathological effects in transgenic mice. All three of these proteins cause cerebellar atrophy and apoptosis of granule neurons (this work; Shmerling et al, 1998; Moore et al, 2001) . Dpl and PrPDN also induce degeneration of cerebellar Purkinje cells when expression is directed to these cells (Flechsig et al, 2003; Anderson et al, 2004) . Each of the proteins also produces a second kind of pathology: vacuolar degeneration of white matter. In the case of PrPDN and Dpl, granule cell death is selectively rescued by wild-type PrP expression in neurons and white matter degeneration by wild-type PrP expression in oligodendrocytes (Radovanovic et al, 2005) . This result suggests that the two pathologies are likely to represent independent toxic effects of the proteins. This conclusion is consistent with our observation that vacuolation in the white matter of the spinal cord and cerebellum is observed in clinically ill Tg(DCR)/Tga20 +/0 mice in the absence of cerebellar granule cell loss.
Mutant forms of PrP can be toxic as a result of protein misfolding and aggregation, leading to altered cellular trafficking and deposition of protease-resistant aggregates in the CNS (Harris, 2003) . In contrast, PrPDCR does not become detergent-insoluble or protease-resistant and it appears to undergo normal trafficking to the cell surface. PrPDN and Dpl also appear to have normal biochemical and cellular properties, to the extent that these have been characterized (Shmerling et al, 1998; Massimino et al, 2004) . Thus, it is likely that PrPDCR, PrPDN, and Dpl act via a common neurotoxic mechanism that is independent of protein aggregation, and that is more likely to be related to an effect on the normal biological activity of PrP C .
Why is PrPDCR so toxic?
A striking feature of our results is the greatly enhanced lethality of PrPDCR compared to PrPDN and Dpl (at equivalent expression levels) and the requirement for much higher levels of wild-type PrP to rescue the Tg(DCR) phenotype. For example, Tg(PrPD32-134)/Prn-p 0/0 mice, which express the mutant protein at B2 Â endogenous levels (using the same promoter as in our Tg(DCR) mice), become ill at approximately 3-5 weeks of age and die at 2-6 months (Shmerling et al, 1998) . A single Prn-p allele (0.5 Â expression level) is sufficient to completely rescue the phenotype of these animals. Several lines of Prn-p 0/0 mice that ectopically express Dpl in brain at levels likely to be similar to those of endogenous PrP become ill at 6-18 months of age (Sakaguchi et al, 1996; Moore et al, 1999; Rossi et al, 2001 ). Again, a single Prn-p allele completely abrogates the phenotype in these animals. In contrast, transgenic mice with 0.5 Â expression level of PrPDCR (four-fold less than PrPD32-134) become ill at a much younger age (4 days on the Prn-p 0/0 background), and supraphysiological levels of wild-type PrP (5 and 6 Â ) ameliorate, but are not sufficient to completely rescue, the neurodegenerative phenotype.
The marked difference between the specific toxic activities of PrPDCR on the one hand and PrPDN/Dpl on the other is most consistent with a model in which these proteins have different affinities for a hypothetical receptor (Tr) that serves to transduce the toxic signal ( Figure 8A-C) . The strong dose dependence that characterizes wild-type PrP rescue of the neurodegenerative phenotype and the fact that much higher expression levels of wild-type PrP are required to reverse the illness of Tg(DCR) mice suggest that wild-type PrP acts by competing with PrPDCR/PrPDN/Dpl for binding to this hypothetical receptor, preventing delivery of the toxic signal (or perhaps promoting delivery of a protective or trophic signal; see below). In this scheme, PrPDCR would have a higher affinity for Tr than PrPDN or Dpl, thus accounting for the greater specific toxicity of PrPDCR. In addition, the affinity of wild-type PrP for Tr would be higher than that of PrPDN/Dpl, but lower than that of PrPDCR. Thus, endogenous levels of wild-type PrP would be sufficient to completely abrogate neurodegeneration in Tg(PrPDN) or Tg(Dpl) mice, but supraphysiological levels would be required to significantly delay illness in Tg(DCR) mice.
Functional and structural roles of the 105-125 region
How does deletion of residues 105-125 alter the biological activity of PrP in such a dramatic way? Five of the first six amino acids of this segment are polar, including three positively charged residues, whereas the last 15 amino acids are all hydrophobic ( Figure 1A) . Strikingly, the 105-125 region of PrP is the most evolutionarily conserved part of the protein, with the positively charged residues and the hydrophobic stretch present in PrP homologs from fish to humans (RiveraMilla et al, 2006) . It is therefore likely that this segment participates in an essential biological function of the protein.
Residues 105-125 lie within a region that plays an important role in determining the membrane topology of PrP. Residues 111-135 constitute a hydrophobic domain that can span the lipid bilayer in transmembrane forms of PrP ( Ctm PrP and Ntm PrP) (Hegde et al, 1998; Stewart et al, 2001) , whereas residues 103-111 function as a 'stop transfer effector' (STE) that regulates membrane insertion of the adjacent hydrophobic segment (Yost et al, 1990) (Figure 1A ). Whether the toxicity of PrPDCR (as well as PrPDN and Dpl) results from impaired ability of these proteins to adopt a transmembrane topology remains to be determined. The hydrophobic domain of PrP has also been implicated in sorting of the protein in polarized cells (Uelhoff et al, 2005) and in binding to certain ligands (Zanata et al, 2002) , functions that might also play a role in the toxicity of PrPDCR.
Based on NMR analysis of recombinant and brainderived PrP, residues 23-125 form a relatively unstructured, N-terminal tail, whereas residues 128-230 constitute a folded domain comprised of three a-helices and two short b-strands flanking helix 1 (Zahn et al, 2000; Hornemann et al, 2004) . Because residues 105-125 lie within the flexible tail, their deletion would not be expected to dramatically alter the C-terminal, folded domain of PrP (Zahn et al, 2000) . These considerations suggest that the toxicity of PrPDCR results from elimination of a critical binding site encompassing residues 105-125 within the flexible tail (Figure 8 ), rather than from significant structural alterations induced in the C-terminal half of the molecule. As both PrPDN and PrPDCR are missing the 105-125 region, the enhanced lethality of the latter must presumably be due to additional binding interactions between PrPDCR and Tr involving residues 32-104.
Neuroprotective and neurotoxic effects of PrP
Paradoxically, PrP has been reported to play a role in both neurotoxic and neuroprotective phenomena (Harris and True, 2006) . On the one hand, PrP C can protect cells from several kinds of pro-apoptotic stimuli (Kuwahara et al, 1999; Bounhar et al, 2001; Brown et al, 2002; Diarra-Mehrpour et al, 2004; McLennan et al, 2004; Li and Harris, 2005; Spudich et al, 2005) . Conversely, PrP promotes cell death in some experimental situations (Brown et al, 1994; Solforosi et al, 2004; Sunyach and Checler, 2005) .
The phenotype of Tg(PrPDCR) and Tg(PrPDN) mice exemplifies the opposing neuroprotective and neurotoxic activities of PrP, as wild-type PrP exhibits a protective effect against the toxic effect of mutant PrP. Our results with Tg(DCR) mice suggest that residues 105-125 are essential for eliciting the neuroprotective activity of PrP, and that deletion of this segment converts PrP from a neuroprotective into a neurotoxic molecule. In terms of the model presented above, we hypothesize that PrP C binding to the hypothetical receptor, Tr, normally delivers a neuroprotective signal ( Figure 8A ). This signal would have to be non-essential, as PrP-null mice display a relatively normal phenotype (Bü eler et al, 1992; Manson et al, 1994) . We postulate that deletion of residues 105-125 alters or subverts the interaction between PrP and Tr in such a way that a neurotoxic rather than a neuroprotective signal is produced ( Figure 8B and C) . This subversion of activity might occur because delivery of a neuroprotective signal requires that PrP bind to Tr at two distinct sites: the 105-125 region and the structured, C-terminal domain. Binding to the C-terminal domain alone, in the absence of binding to the 105-125 region, might produce a neurotoxic rather than a neuroprotective signal. The change from neuroprotective to neurotoxic signaling presumably involves a conformational alteration in Tr.
The model outlined here is different from that previously proposed to explain the neurotoxicity of PrPDN and Dpl (Shmerling et al, 1998 ). The latter model, which is based on a loss rather than a subversion of function, postulates the existence of two hypothetical molecules, one of which is a ligand that binds to PrP and the other a receptor that binds the ligand when PrP is absent.
A possible mechanism for the toxicity of PrP106-126 and PrP
Sc
It is striking that a synthetic peptide comprising human PrP residues 106-126 (equivalent to residues 105-125 in murine PrP, the region deleted in PrPDCR) has been reported to be toxic to neurons cultured from Prn-p +/+ but not Prn-p 0/0 mice Brown et al, 1994; Fioriti et al, 2005) . This result suggests the hypothesis that the peptide alters interaction between PrP and the hypothetical transducer Tr by competitively blocking binding within the 105-125 region of PrP ( Figure 8D ). This would then produce a toxic signal equivalent to the one elicited by PrPDCR, which lacks the 105-125 domain. In the absence of PrP C , no signal would be delivered and the peptide would have no effect.
A similar mechanism could be invoked to explain the toxic effect of PrP Sc , which also appears to require expression of PrP C Mallucci et al, 2003) . In this case, PrP Sc might perturb interaction between PrP C and Tr by blocking binding within the 105-125 domain, thereby producing a toxic signal equivalent to the one elicited PrPDCR and by PrP106-126. Consistent with this model, PrP106-126 displays certain biochemical properties typical of PrP Sc (aggregation, protease resistance), and its mechanism of toxicity has been proposed to be similar to that of PrP Sc (Selvaggini et al, 1993) . In addition, PrP Sc appears to be conformationally altered in the 105-125 region (Peretz et al, 1997) .
Future studies
The work presented here identifies residues 105-125 as a critical functional domain of PrP whose deletion endows the protein with powerful neurotoxic properties. To further elucidate the molecular basis of this effect, it will be necessary to identify other proteins, such as the hypothetical receptor Tr, that play a role in transducing the neurotoxic and neuroprotective signals that emanate from PrP. As PrPDCR appears to engage the signal transducing machinery with very high affinity, it may facilitate discovery of PrP-interacting proteins using biochemical methods. The enhanced toxic potency of PrPDCR may also allow the development of improved cell culture models to analyze the signaling pathways activated by PrP. Thus far, there has been only limited success in reproducing the toxic effects of PrPDN and Dpl in cultured cells (Drisaldi et al, 2004) . Finally, it will be of great interest to further explore the relationship between the neurotoxic pathways activated by PrP Sc and PrPDCR, and to determine whether common mechanisms are involved.
Materials and methods
Production of transgenic mice
A cDNA encoding murine PrPDCR (PrPD105-125) was generated by preparing the 5 0 and 3 0 halves of the cDNA separately, and then introducing these into the cloning vector in a three-part ligation reaction. The 5 0 half of the cDNA was amplified by PCR using as a template pcDNA3 containing wild-type mouse PrP with a 3F4 epitope tag (Lehmann and Harris, 1995) . The upstream primer was Tg51 (5 0 -GTACAGGACCAAGCTTAGTCTCGAGCCATGGCGAACCTTG GCTACTGGCTGCTG-3 0 ) and the downstream primer was Tg31 (5 0 -GCTCATGGCGCTCCCCAGCATGTAGCCTGGTTTGCTGGGCTTGTTC CACTGATT-3 0 ). Primer Tg51 contained a HindIII restriction site and primer Tg31 contained the 104-126 junction sequence and an HaeII restriction site. The resulting PCR product was digested with HindIII and HaeII. A fragment encoding the 3 0 half of PrPDCR was generated by digesting wild-type mouse PrP/pcDNA3 with HaeII and BamHI. The 5 0 and 3 0 halves of the PrPDCR cDNA were then ligated into pcDNA3.1( þ ) (Invitrogen, Carlsbad, CA). A fragment encoding the complete PrPDCR sequence was then released from the resulting plasmid by digestion with HindIII/BamHI, and blunted by treatment with Klenow polymerase. The blunted fragment was then ligated into transgenic expression vector MoPrP.Xho (Borchelt et al, 1996) that had been cleaved with XhoI and then blunted. Recombinant plasmid with the insert in the correct orientation was selected by EcoRI digestion and sequencing. The transgene was excised from the recombinant plasmid by digestion with NotI, purified on GFX PCR DNA purification columns (Amersham Biosciences), and injected into the pronuclei of fertilized eggs from an F 2 cross of C57BL/6J Â CBA/J F 1 parental mice.
Transgenic founders were bred to the following mouse strains: C57BL/6J Â CBA/J parental mice; Prn-p 0/0 mice obtained from Charles Weissmann that had been produced on a 129 Â C57BL/6J background (Bü eler et al, 1992) ; or Tga20 mice to maintain the lines.
Mice were genotyped by PCR analysis of tail DNA prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). The primer pairs used were as follows: P1 and P4 (Chiesa et al, 1998) which amplify both the PrPDCR and Tga20 transgenes; DCR (5 0 -CCTCGAAGCTTAGTCTCGAGCC-3 0 ) and E4 (5'-TCATGGC GCTCCCCAGCATGTA-3'), which amplify only the PrPDCR transgene; and P2 and P4 (Chiesa et al, 1998) which amplify the Prn-p + and Prn-p 0 alleles.
Histology
Animals were perfusion-fixed and paraffin sections of brain and spinal cord were stained with hematoxylin and eosin or with anti-GFAP antibodies as described previously (Chiesa et al, 1998) , except that GFAP antibodies were visualized using AlexaFluor 594-coupled goat anti-rabbit IgG (Invitrogen). Purkinje cells were visualized by staining sections with a rabbit antibody to calbindin (Chemicon, Temecula, CA), followed by visualization with AlexaFluor 488-coupled goat anti-rabbit IgG (Invitrogen). For TUNEL, paraffin sections prepared as above were treated in permeabilization solution (0.1 M citrate buffer, pH 6.0, 0.05% Tween 20) and labeled with In Situ Cell Death Detection Kit according to the manufacturer's protocol (Roche Diagnostics, Indianapolis, IN). Caspase-3 activation was monitored using an anti-activated caspase-3 antibody (Cell Signaling Technology, Beverly, MA) and visualized using the peroxidase-anti-peroxidase method as described previously (Young et al, 2005) . Sections were stained with either DAPI or hematoxylin to visualize cell nuclei.
